Clinical studies recruiting near Brighton

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · National Cancer Institute (NCI) · NCT05564390 Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Phase N/A · Galderma Investigational Site 7065 · Galderma R&D · NCT06988605 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · NRG Oncology · NCT05624996 Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · National Cancer Institute (NCI) · NCT07437950 A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Pa
Phase 4 · Metro Boston Clinical Partners · Eli Lilly and Company · NCT06857942 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · Alliance for Clinical Trials in Oncology · NCT07321652 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Trinity Health IHA Medical Group Hematology Oncology - Brigh · Alliance for Clinical Trials in Oncology · NCT07091617 Visugromab in Cachexia International Trial
Phase 2/Phase 3 · Royal Sussex County Hospital · CatalYm GmbH · NCT07112196 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · SWOG Cancer Research Network · NCT06769126 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · Trinity Health Medical Center - Brighton · NRG Oncology · NCT05946213 Molecular Genetics Studies of Cancer Patients and Their Relatives
Phase N/A · Steward Saint Elizabeth's Medical Center · City of Hope Medical Center · NCT04185935 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Royal County Sussex Hospital · Boehringer Ingelheim · NCT06531824 Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Proto
Phase 3 · MetroBoston Clinical Partners, LLC · Tanabe Pharma America, Inc. · NCT05005975 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Intermountain Health Platte Valley Hospital · NRG Oncology · NCT05174169 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · Alliance for Clinical Trials in Oncology · NCT06931340 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · Alliance for Clinical Trials in Oncology · NCT06876714 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · National Cancer Institute (NCI) · NCT04269902 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · University of Michigan - Brighton Center for Specialty Care · Canadian Cancer Trials Group · NCT06592924 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · Alliance for Clinical Trials in Oncology · NCT06632977 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants Wi
Phase 3 · Research Site · AstraZeneca · NCT05211895 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Trinity Health IHA Medical Group Hematology Oncology - Brigh · Alliance for Clinical Trials in Oncology · NCT04242095 Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
NA · Royal Sussex County Hospital · Abbott Medical Devices · NCT07523620 A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
Phase 2 · University Hospitals Sussex NHS Foundation Trust · Imperial College London · NCT04319367 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · National Cancer Institute (NCI) · NCT05256225 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid
Phase 2 · Research Site · AstraZeneca · NCT07215702 Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Phase 3 · University Hospitals Sussex · Iperboreal Pharma Srl · NCT03994471 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · National Cancer Institute (NCI) · NCT05554393 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · National Cancer Institute (NCI) · NCT06498635 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Brigh · NRG Oncology · NCT05327686

Look up another city

Look up another condition